{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:17:19Z","timestamp":1785802639203,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s41669-022-00363-1","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T13:07:51Z","timestamp":1663247271000},"page":"859-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada"],"prefix":"10.1007","volume":"6","author":[{"given":"Moogeh","family":"Baharnoori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virender","family":"Bhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Clift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souka\u00efna","family":"Mouallif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Adlard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Blanchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barkha P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"issue":"2","key":"363_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96\u2013120.","journal-title":"Mult Scler"},{"issue":"2","key":"363_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/135245850000600207","volume":"6","author":"DT Grima","year":"2000","unstructured":"Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6(2):91\u20138.","journal-title":"Mult Scler"},{"issue":"4","key":"363_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1017\/cjn.2020.66","volume":"47","author":"MS Freedman","year":"2020","unstructured":"Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, et al. Treatment optimization in multiple sclerosis: Canadian MS working group recommendations. Can J Neurol Sci. 2020;47(4):437\u201355.","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"363_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Haring DA, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10(6):495\u2013507.","journal-title":"J Comp Eff Res."},{"issue":"18","key":"363_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/cer-2020-0122","volume":"9","author":"IA Samjoo","year":"2020","unstructured":"Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Haring DA, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255\u201374.","journal-title":"J Comp Eff Res."},{"issue":"4","key":"363_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307\u201316.","journal-title":"Lancet Neurol"},{"issue":"4","key":"363_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273\u20139.","journal-title":"Pract Neurol"},{"issue":"3","key":"363_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"363_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"key":"363_CR10","unstructured":"Canadian Agency for Drugs and Technologies in Health. Procedures for CADTH reimbursement reviews. https:\/\/www.cadth.ca\/sites\/default\/files\/Drug_Review_Process\/CADTH_Drug_Reimbursement_Review_Procedures.pdf. Accessed 15 June 2022."},{"key":"363_CR11","unstructured":"Canadian Agency for Drugs and Technologies in Health Methods and Guidelines. Guidelines for the economic evaluation of health technologies: Canada: 4th edition. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf. Accessed 15 June 2022."},{"key":"363_CR12","unstructured":"Canadian Agency for Drugs and Technologies in Health. Procedures for CADTH reimbursement reviews. 2021. https:\/\/cadth.ca\/sites\/default\/files\/Drug_Review_Process\/CADTH_Drug_Reimbursement_Review_Procedures.pdf. Accessed 20 Apr 2021."},{"key":"363_CR13","unstructured":"Black C. Assessing the potential impact of recommendations made through the CADTH Common Drug Review (CDR) program. CADTH Symposium. https:\/\/www.cadth.ca\/sites\/default\/files\/symp-2019\/presentations\/april15-2019\/B5-presentation-cblack.pdf. Accessed 15 June 2022."},{"key":"363_CR14","doi-asserted-by":"publisher","first-page":"A347","DOI":"10.1016\/j.jval.2016.09.821","volume":"19","author":"EA Griffiths","year":"2016","unstructured":"Griffiths EA, Vadlamudi NK. CADTH\u2019s $50,000 cost-effectiveness threshold: fact or fiction? Value Health. 2016;19:A347\u2013766.","journal-title":"Value Health."},{"key":"363_CR15","unstructured":"Health Canada. KESIMPTA (ofatumumab injection) Product Monograph. Health Canada Drug Product Database. 2021. https:\/\/pdf.hres.ca\/dpd_pm\/00059817.PDF. Accessed 20 Apr 2021."},{"issue":"1","key":"363_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004073","volume":"4","author":"J Palace","year":"2014","unstructured":"Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4(1): e004073.","journal-title":"BMJ Open"},{"issue":"Pt 1","key":"363_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/brain\/112.1.133","volume":"112","author":"BG Weinshenker","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133\u201346.","journal-title":"Brain"},{"issue":"7","key":"363_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","volume":"21","author":"R Hettle","year":"2018","unstructured":"Hettle R, Harty G, Wong SL. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J Med Econ. 2018;21(7):676\u201386.","journal-title":"J Med Econ"},{"issue":"2","key":"363_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jval.2018.08.011","volume":"22","author":"V Chirikov","year":"2019","unstructured":"Chirikov V, Ma I, Joshi N, Patel D, Smith A, Giambrone C, et al. Cost-effectiveness of alemtuzumab in the treatment of relapsing forms of multiple sclerosis in the United States. Value Health. 2019;22(2):168\u201376.","journal-title":"Value Health."},{"issue":"4","key":"363_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","volume":"19","author":"J Mauskopf","year":"2016","unstructured":"Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2016;19(4):432\u201342.","journal-title":"J Med Econ"},{"key":"363_CR21","doi-asserted-by":"crossref","unstructured":"Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976\u20131980. Acta Neurol Scand. 1982;65(4):248\u201366.","DOI":"10.1111\/j.1600-0404.1982.tb03084.x"},{"issue":"1","key":"363_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10(1):54\u201360.","journal-title":"Value Health."},{"issue":"10","key":"363_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075416","volume":"8","author":"EM Mowry","year":"2013","unstructured":"Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, et al. Multiple sclerosis susceptibility genes: associations with relapse severity and recovery. PLoS ONE. 2013;8(10): e75416.","journal-title":"PLoS ONE"},{"key":"363_CR24","unstructured":"Statistics Canada. Life tables, Canada, provinces and territories, Table 13-10-0114-01 (2017-2019, qx column). 2019. https:\/\/www150.statcan.gc.ca\/n1\/en\/catalogue\/84-537-X. Accessed 20 Feb 2021."},{"issue":"2","key":"363_CR25","first-page":"101","volume":"29","author":"RJ Pokorski","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29(2):101\u20136.","journal-title":"J Insur Med"},{"key":"363_CR26","unstructured":"National Institute for Health and Care Excellence. Ocrelizumab for treating relapsing\u2013remitting multiple sclerosis Technology appraisal guidance [TA533]. 2018 https:\/\/www.nice.org.uk\/guidance\/ta533\/resources\/ocrelizumab-for-treating-relapsingremitting-multiple-sclerosis-pdf-82606899260869. Accessed 7 Sept 2021."},{"key":"363_CR27","unstructured":"Canadian Agency for Drugs and Technologies in Health. CDR pharmacoeconomic review report for Mavenclad. 2018."},{"key":"363_CR28","unstructured":"Canadian Agency for Drugs and Technologies in Health. CDR pharmacoeconomic review report for Lemtrada. 2015. https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0405_Lemtrada_RRMS_PE_Report.pdf. Accessed 20 May 2020."},{"issue":"2","key":"363_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1191\/1352458505ms1137oa","volume":"11","author":"MB Patwardhan","year":"2005","unstructured":"Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11(2):232\u20139.","journal-title":"Mult Scler"},{"issue":"1","key":"363_CR30","first-page":"e11","volume":"19","author":"K Karampampa","year":"2012","unstructured":"Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol. 2012;19(1):e11-25.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"363_CR31","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH therapeutic review. Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis [Internet]\/. 2013. http:\/\/www.cadth.ca\/media\/pdf\/TR0004_RRMS_ScienceReport_e.pdf. Accessed 20 May 2020."},{"key":"363_CR32","unstructured":"Government of Ontario. Ontario Drug Benefit Formuarly. 2021. https:\/\/www.formulary.health.gov.on.ca\/formulary\/. Accessed 6 May 2021."},{"key":"363_CR33","unstructured":"Government of Ontario. Ontario Exceptional Access Program Formulary. 2021. http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/odbf\/odbf_except_access.aspx. Accessed 6 May 2021."},{"key":"363_CR34","unstructured":"Ontario Case Costing Initiative. Costing analysis tool. 2018. https:\/\/hsimi.ca\/occp\/occpreports\/. Accessed 20 Apr 2021."},{"key":"363_CR35","unstructured":"Ontario Ministry of Health. Schedule of benefits for laboratory services (effective July 1, 2020). http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/lab\/lab_mn2020.pdf. Accessed 20 Apr 2021."},{"key":"363_CR36","unstructured":"Ontario Ministry of Health. Schedule of benefits, physician services under the health insurance act (effective march 14, 2021). http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/physserv\/sob_master20200306.pdf. Accessed 20 Apr 2021."},{"issue":"2","key":"363_CR37","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.3747\/co.20.1223","volume":"20","author":"VC Tam","year":"2013","unstructured":"Tam VC, Ko YJ, Mittmann N, Cheung MC, Kumar K, Hassan S, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013;20(2):e90\u2013106.","journal-title":"Curr Oncol"},{"key":"363_CR38","unstructured":"Government of Alberta. Alberta interactive drug benefit list. 2021. https:\/\/idbl.ab.bluecross.ca\/idbl\/load.do. Accessed 20 Apr 2021."},{"key":"363_CR39","unstructured":"Statistics Canada. Consumer Price Index [Health care], monthly, not seasonally adjusted; Table 18-10-0004-01. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000401. Accessed 13 Mar 2021."},{"issue":"6","key":"363_CR40","doi-asserted-by":"publisher","first-page":"E155","DOI":"10.1503\/cmaj.170317","volume":"190","author":"JR Guertin","year":"2018","unstructured":"Guertin JR, Feeny D, Tarride JE. Age- and sex-specific Canadian utility norms, based on the 2013\u20132014 Canadian Community Health Survey. CMAJ. 2018;190(6):E155\u201361.","journal-title":"CMAJ"},{"issue":"5","key":"363_CR41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1524-4733.2008.00485.x","volume":"12","author":"P Tappenden","year":"2009","unstructured":"Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health. 2009;12(5):657\u201365.","journal-title":"Value Health."},{"key":"363_CR42","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/1472-6963-13-346","volume":"13","author":"S Acaster","year":"2013","unstructured":"Acaster S, Perard R, Chauhan D, Lloyd AJ. A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis. BMC Health Serv Res. 2013;13:346.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"363_CR43","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1524-4733.2004.75007.x","volume":"7","author":"LA Prosser","year":"2004","unstructured":"Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7(5):554\u201368.","journal-title":"Value Health."},{"key":"363_CR44","unstructured":"Government of Canada. Job Bank: Wages for registered nurses and registered psychiatric nurses. 2021. https:\/\/www.jobbank.gc.ca\/wagereport\/occupation\/993. Accessed 20 Apr 2021."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00363-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00363-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00363-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T20:40:09Z","timestamp":1666730409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00363-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["363"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00363-1","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"7 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Novartis Pharmaceutical Canada Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: SM and FB are employees of Novartis Pharmaceutical Canada Inc. KT, BPP and DG are employees of CRG-EVERSANA Canada Inc., which received funding from Novartis Pharmaceutical Canada Inc. to conduct this analysis. NA is an employee of Novartis International AG. PC is an employee of Novartis Ireland Limited. VB has received compensation for activity with Biogen, BMS, Celgene, EMD Serono, Genzyme, Novartis, Roche, Sanofi, and Teva. MB has received compensation for advisory board\/consulting services to Alexion, Biogen, BMS, EMD Serono, Novartis, Pendopharm, Genzyme, Teva Neuroscience, Roche, and Xfacto communications. FC has received compensation for activity with Biogen, BMS, Celgene, EMD Serono, Genzyme, Novartis, Roche, Sanofi, and Teva.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The economic model used for analyses is not publicly available at this time.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SM, FB, KT, and DG contributed to the study conception and design. KT, BPP, and DG contributed to data analysis. MB, VB, and FC contributed to clinical interpretation of the data. The first draft of the manuscript was written by KT and BPP and all authors reviewed the manuscript, made substantial contributions to the content, and approved the final draft.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}